EC-5026 is under clinical development by Eicosis and currently in Phase I for Diabetic Neuropathic Pain. According to GlobalData, Phase I drugs for Diabetic Neuropathic Pain have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EC-5026’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EC-5026 overview
EC-5026 is under development for the treatment of diabetic neuropathic pain, arrhythmogenic cardiomyopathy, chronic pain and inflammatory pain. The drug candidate is administered orally. It is a small molecule which acts by targeting soluble epoxide hydrolase (sEH).
Eicosis overview
Eicosis is an health care company which develops new effective and safe oral medicines to help people and companions suffering from pain. The company is committed to improve the lives of people suffering from pain, helping them feel themselves again. Eicosis is headquartered in Davis, California, the US.
For a complete picture of EC-5026’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
